News

Advancing Pharmaceutical Manufacturing in Central Virginia: The Success of the GO Virginia Grant

Activation Capital is proud to announce the successful closeout of a pivotal GO Virginia grant, addressing the urgent need to secure access to and reduce the costs of essential medicines. This grant laid the foundation for Central Virginia’s growth as a hub for advanced pharmaceutical manufacturing (APM) by leveraging the region’s strengths in advanced manufacturing, life sciences, and logistics. This funding also helped spur the creation of the Alliance for Building Better Medicine, a key collaboration between public and private stakeholders, aimed at strengthening the region’s infrastructure, workforce, and supply chain capabilities.

The Road to Building a Pharma Hub

The GO Virginia initiative set out with a clear vision: to position Central Virginia as a competitive force in the APM sector with the overarching goal of reshoring essential medicine manufacturing within the United States. The initiative focused on creating a robust regional alliance that would drive strategic development in the areas of infrastructure, workforce training, and supply chain enhancements, all while fostering regional collaboration and networking.

This seed funding allowed stakeholders to lay the foundation for a thriving cluster, enabling the region to achieve key outcomes, including:

  • Creation of 260 new jobs and the expansion of 17 businesses.
  • Secured $52 million in additional funding through the EDA’s Build Back Better Regional Challenge grant.
  • Established a world-class talent pipeline through successful workforce programs, including the creation of the Advanced Pharmaceutical Manufacturing Technician Certificate (APMTC) in collaboration with Brightpoint Community College and the Community College Workforce Alliance (CCWA), and a joint Pharmaceutical Engineering program in collaboration with VCU and VSU.
  • The formation of working groups targeting supply chain, laboratory facilities, workforce development, and communications.
  • Networking with industry leaders and showcasing the region at major conferences such as BIO International, CPhI, DCAT, and THRiVE.

The initiative has positioned Central Virginia to continue its growth as a national leader in pharmaceutical manufacturing, innovation, and supply chain resilience.

Moving Forward

The groundwork established by the GO Virginia grant is already paying dividends, but the momentum doesn’t stop here. Looking ahead, the initiative is well-positioned for continued growth, with a strong administrative foundation and development across supply chain, facilities, and workforce sectors. In collaboration with VCU, the program is leveraging a $1M National Science Foundation (NSF) Regional Innovation Engines Development grant to accelerate workforce and DEIA development and strategic planning focused on APM and R&D. Additionally, preparations are underway for an NSF Engines Type 2 application, aimed at ensuring the program’s long-term sustainability and further solidifying Central Virginia as a leader in advanced pharmaceutical manufacturing.

Additionally, funding support through SBA and GO Virginia programs is fostering entrepreneurship, innovation, and startup ecosystems across the region. These efforts align with similar initiatives in Charlottesville, focused on life sciences, and Blacksburg, focused on advanced manufacturing. The collaboration between regions demonstrates a unified commitment to building a statewide biotech hub, with each area contributing unique expertise. Together, these initiatives will drive the development of a robust life science, pharmaceutical, and advanced manufacturing cluster throughout Virginia, creating new opportunities for innovation and growth.

Learn more about how Activation Capital continues to drive regional growth and innovation at Activation Capital.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation